The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the USA, followed by the establishment of cord blood banks across the globe. However, the history of cord blood stem cell transplantation begins much earlier than that. [Read more…]
Ways to Curb the Sky-high Costs of CAR-T Cell Therapy
CAR-T therapy has revolutionized cancer treatment, offering a personalized approach that uses genetically modified T cells to target and destroy cancer cells. However, this breakthrough treatment comes at a steep price. In the U.S., CAR-T therapies are priced between $300,000 and $600,000, and when factoring in the costs of treating adverse reactions and hospital stays, the total expenditure can exceed $1,000,000. The high cost makes it inaccessible for many patients and poses a challenge for healthcare systems worldwide.
To address this issue, experts and industry leaders have proposed several strategies to reduce the cost of CAR-T therapy while maintaining its efficacy and accessibility. [Read more…]
Global Trends in Cord Blood and Newborn Stem Cell Banking
Today, nearly 80% of the global cord blood market is controlled by the world’s 12 largest cord blood banking operators. This is an incredible figure, given that the the cord blood industry grew to over 400 market participants in the early 2000’s but has consolidated dramatically since that time. [Read more…]
Exosomes: Company Spotlights from “A” to “Z”
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.
With at least 26,805 scientific articles published about exosomes and 301 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. The term “exosomes” has become an increasingly common Search Term on Google over the past 10 years, as shown in the graph below: [Read more…]
CAR-T Market Leaders in 2026: Leaders, Innovators, and Game-Changing Tech
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the landscape of oncology, offering personalized cellular solutions for hematologic malignancies and expanding into solid tumors and autoimmune disorders. By engineering a patient’s own T-cells to recognize and destroy cancer cells, CAR-T therapies provide unprecedented efficacy, often in patient populations with limited treatment options.
The global CAR-T market has grown substantially in recent years, climbing to 13 approvals worldwide. Seven of these therapies have been approved by the U.S. FDA, with subsequent approvals in other major healthcare markets. These therapies include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl. Beyond the U.S., four CAR-T therapies (Relma-cel, Fucaso, Yuanruida, and Zever-cel) have been approved by China’s National Medical Products Administration (NMPA), while two therapies, NexCAR19 and Qartemi, have received approval from India’s Central Drugs Standard Control Organisation (CDSCO). [Read more…]
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 334
- Next Page »